Loading…
Zhejiang-based active pharmaceutical ingredient and CDMO manufacturer exporting to generic-drug makers abroad.
Zhejiang-based active pharmaceutical ingredient and CDMO manufacturer exporting to generic-drug makers abroad.
In one line: A small Chinese API/CDMO exporter.
Moat: none (scale). Commodity API/CDMO producer competing mainly on cost and regulatory filings.
Headquarters: Taizhou, Zhejiang, China · Employees: 2,026
Size Aurisco Pharmaceutical (605116.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.13B, the 2067th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥18.60 on 6 Nov 2026.
Performance Over six months the shares fell 17.7%, against -14.4% for the median peer and -16.4% for the China market (cap-weighted) — 9th lowest of 21 in its peer set.
Growth Revenue grew 8.7% over the last twelve months (peer median -2.5%); the operating margin is 28.3% (peer median 7.6%).
Valuation It trades at 15.4× forward earnings against a peer median of 26.5× (4th cheapest of 13).
Price implies For today's price to make sense, revenue must grow about 1% a year for seven years (Req g). Recent delivered growth is +19%, so the hurdle is -17 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 7.1 points above its cost of capital (5.0% WACC).
Next results Next results expected around 22 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.70B | CN¥1.69B | CN¥1.47B | CN¥1.26B | CN¥1.00B |
| Revenue growth | — | +15% | +17% | +25% | — |
| Gross profit | CN¥931M | CN¥967M | CN¥826M | CN¥671M | CN¥491M |
| EBITDA | CN¥647M | CN¥658M | CN¥474M | CN¥358M | CN¥279M |
| Net income | CN¥373M | CN¥449M | CN¥355M | CN¥289M | CN¥211M |
| Free cash flow | CN¥35.0M | CN¥78.0M | -CN¥204M | CN¥80.2M | -CN¥49.6M |
| Capital expenditure | CN¥388M | CN¥350M | CN¥540M | CN¥305M | CN¥216M |
| Total debt | CN¥1.03B | CN¥1.03B | CN¥1.04B | CN¥271M | CN¥145M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Aurisco Pharmaceutical 605116.SS | $1.13B | -18% | +9% | 28% | 15.4× | 1.5% |
| Zhejiang Huahai Pharmaceutical 600521.SS | $3.86B | +8% | +10% | 12% | 22.1× | 7.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 605116.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -6.2% | -6.1% | 11th highest of 21 |
| 6-month return | -17.7% | -14.4% | 9th lowest of 21 |
| Distance from 52-week high | -47.7% | -35.5% | 7th lowest of 21 |
| Revenue growth (TTM) | +8.7% | -2.5% | 8th highest of 19 |
| Operating margin | 28.3% | 7.6% | highest of 19 |
| Forward P/E | 15.4× | 26.5× | 4th cheapest of 13 |
| Growth the price implies (Req g, 7 yrs) | 1.5% | 7.0% | 4th least demanding of 13 |
| Growth delivered (Del g) | +18.7% | +6.1% | 3rd highest of 13 |
| Hurdle (Req g minus delivered) | -17.3 pp | +0.2 pp | 2nd least demanding of 13 |
| ROIC minus cost of capital | +7.1 pp | -0.2 pp | 2nd highest of 18 |
| EV / EBITDA | 12.1× | n/a | — |
| Net debt / EBITDA | 0.5× | n/a | — |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Aurisco Pharmaceutical 605116.SS | China | $1.13B | -18% | +9% | 28% | 15.4× | 1.5% | +18.7% |
| Shanghai Yizhong Pharmaceutical 688091.SS | China | $1.13B | -34% | +32% | 14% | n/a | n/a | n/a |
| Zhejiang Jolly Pharmaceutical 300181.SZ | China | $1.13B | -18% | +17% | 20% | 12.8× | 1.1% | +22.8% |
| MedinCell MEDCL.PA | France | $1.15B | -1% | -23% | -131% | n/a | n/a | n/a |
| ST Pharm 237690.KS | South Korea | $1.12B | -52% | +26% | 18% | 27.9× | n/a | n/a |
| Seaport Therapeutics SPTX | United States | $1.15B | +34% | n/a | n/a | n/a | n/a | n/a |
| Shandong Lukang Pharmaceutical 600789.SS | China | $1.11B | -13% | -7% | 3% | n/a | 3.3% | +6.5% |
| Blue Jet Healthcare BLUEJET.NS | India | $1.11B | +13% | -28% | 28% | 32.5× | 49.0% | +13.8% |
| Bio-Thera Solutions 688177.SS | China | $1.10B | -14% | +24% | -44% | n/a | n/a | n/a |
| North China Pharmaceutical 600812.SS | China | $1.17B | -8% | -21% | 5% | n/a | 1.4% | -4.2% |
| Ningbo Menovo Pharmaceutical 603538.SS | China | $1.10B | -51% | +19% | 9% | 49.2× | 13.9% | +4.9% |
| Shanghai InnoStar Bio-tech 688710.SS | China | $1.17B | +28% | +24% | 6% | 85.2× | 16.2% | +19.4% |
| Jiangxi Fushine Pharmaceutical 300497.SZ | China | $1.10B | -29% | +103% | 24% | 10.6× | 8.6% | -4.5% |
| Cosmo CMHC.SW | Switzerland | $1.17B | -25% | -45% | -13% | 432.6× | n/a | n/a |
| Vetoquinol VETO.PA | France | $1.17B | +22% | -1% | 15% | 15.8× | -3.0% | +4.2% |
| Chongqing Taiji Industry (Group) 600129.SS | China | $1.09B | -15% | -4% | 2% | 26.5× | n/a | n/a |
| Tianjin Ringpu Bio-technology 300119.SZ | China | $1.18B | -4% | -9% | 11% | 19.6× | 5.8% | +11.3% |
| GC Biopharma 006280.KS | South Korea | $1.18B | +2% | -3% | 4% | 5.0× | 8.3% | +5.8% |
| Chengdu Easton Biopharmaceuticals 688513.SS | China | $1.09B | -35% | -2% | 13% | 26.5× | 5.5% | +7.7% |
| BeBetter Med 688759.SS | China | $1.08B | -49% | n/a | n/a | n/a | n/a | n/a |
| InventisBio 688382.SS | China | $1.19B | -41% | -61% | -563% | n/a | 10.4% | -60.6% |